Analyst Reco. Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Market Closed - Nasdaq Other stock markets 01:30:00 08/05/2024 am IST			5-day change	1st Jan Change
38.44 ^USD	+0.37%		+14.34%	+50.98%

03/05	Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53	MT
02/05	Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53	03/05	MT
Oppenheimer Starts Kymera Therapeutics With Outperform Rating, $53 Price Target	22/04	MT
Truist Ups Price Target on Kymera Therapeutics to $54 From $41, Keeps Buy Rating	01/03	MT
Piper Sandler Raises Price Target on Kymera Therapeutics to $56 From $39, Maintains Overweight Rating	27/02	MT
B. Riley Adjusts Kymera Therapeutics' Price Target to $31 From $16, Keeps Neutral Rating	23/02	MT
Wolfe Research Starts Kymera Therapeutics With Peer Perform Rating	15/02	MT
Morgan Stanley Raises Price Target on Kymera Therapeutics to $33 From $24, Keeps Equalweight Rating	08/01	MT
BofA Securities Downgrades Kymera Therapeutics to Neutral From Buy, Price Target is $30	03/01	MT
Morgan Stanley Adjusts Kymera Therapeutics' Price Target to $24 From $37, Maintains Equalweight Rating	13/11	MT
HC Wainwright Adjusts Price Target on Kymera Therapeutics to $30 From $85, Maintains Buy Rating	03/11	MT
B. Riley Lowers Kymera Therapeutics' PT to $16 From $37 Following Disappointing Oncology Updates, Keeps Neutral Rating	03/11	MT
Morgan Stanley Trims Price Target on Kymera Therapeutics to $37 From $39, Maintains Equalweight Rating	29/23/29	MT
Stifel Raises Kymera Therapeutics' Price Target to $52 From $48, Buy Rating Maintained	07/23/07	MT
Credit Suisse Adjusts Kymera Therapeutics' Price Target to $37 From $36, Keeps Neutral Rating	04/23/04	MT
Truist Initiates Kymera Therapeutics at Buy With $50 Price Target	30/23/30	MT
Morgan Stanley Adjusts Price Target on Kymera Therapeutics to $39 From $41, Maintains Equal-Weight Rating	09/23/09	MT
Raymond James Upgrades Kymera Therapeutics to Outperform From Market Perform, Price Target is $38	05/23/05	MT
Credit Suisse Lowers Kymera Therapeutics' PT to $36 From $39, Notes Lack of Meaningful Catalysts in 2023; Retains Neutral Rating	05/23/05	MT
Credit Suisse Raises Kymera Therapeutics' Price Target to $39 From $32, Keeps Neutral Rating	24/23/24	MT
Wells Fargo Ups Price Target on Kymera Therapeutics to $42 From $40, Maintains Overweight Rating	03/23/03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Analyst Reco.

Filters